HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 8, August 2016 – Novel Technologies for Antibody Drug Discovery in Japan       » Global Experts Convene to Discuss China's Plan for Diabetes Prevention and Rehabilitation in 2016       » Butterflies Offer Climate Scientists Ecological Insights       » Thermal Stability of Camelid Single Domain VHH Antibody       » That Gut Feeling: How A Healthy Digestive System Has Everything To Do With It       » World Heart Day - At the Heart of Health      
BIOBOARD - JAPAN
Daiichi Sankyo and Amplimmune announce strategic alliance to develop AMP-110 therapy for autoimmune disease
Daiichi Sankyo, Co., Ltd. and Amplimmune, Inc. announced that they have entered into a broad strategic collaboration to develop a new therapeutic protein, AMP-110 (B7-H4 fusion protein). The collaboration will focus on development of AMP-110, a potential immune modulation therapy for autoimmune diseases. This proprietary, first-in-class biologic works by blocking inflammatory T cell differentiation. The parties expect to initiate a Phase I clinical study for the compound for the treatment of an autoimmune disease indication in the first half of 2013.

Under the terms of the agreement, Daiichi Sankyo will pay Amplimmune an undisclosed option fee and provide more than $50 million to reimburse past and planned research and development costs for AMP-110, including funding for future development through a Phase II (Proof of Concept Study, POC study).

Amplimmune also will be eligible to receive additional program milestone payments during the collaboration period. Through the POC study, Daiichi Sankyo will have an exclusive option to acquire the AMP-110 program.

Under the terms of the agreement, Amplimmune will be responsible for manufacturing clinical supplies, regulatory filings and conducting clinical trials through a POC study in autoimmunity. Amplimmune and Daiichi Sankyo expect to collaborate on research to further elucidate the characteristic of AMP-110 and to identify potential biomarkers to predict patient response to AMP-110. If Daiichi Sankyo exercises its exclusive option to acquire the AMP-110 program, then following such acquisition Daiichi Sankyo will be solely responsible for all future development, manufacturing and commercialization.

“This collaboration strengthens our commitment to working with partners that are at the forefront of science” said Glenn Gormley, MD, PhD, global head of R&D, senior executive officer of Daiichi Sankyo. “Immune modulation therapy is one of the exciting areas of autoimmune disease research that has the potential to meet an unmet medical need. As a Global Pharma Innovator, identifying and meeting unmet medical needs is an important part of Daiichi Sankyo’s mission. We are excited to start with the first trial.”

“We are very pleased to be collaborating with Daiichi Sankyo on AMP-110” said Michael S. Richman, Amplimmune’s President and Chief Executive Officer.

Richman continued, “This unique transaction allows Amplimmune to collaborate with an important and well-respected partner and positions the program for an acquisition that will provide significant value for both Daiichi Sankyo and our shareholders.”

Click here for the complete issue.

NEWS CRUNCH  
news CPhI's Pre-Connect Congress outlines current trends in pharma
news World Population Day 2016
news NUS Student Clinches Top Prize at National Smart Mapping Competition with Cutting-Edge Food Security Solution
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Big Data in Healthcare
December:
Evidence-based TCM
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com or Mr Edward
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy